Penicillamine-d3
(Synonyms: D-(-)-Penicillamine-d3) 目录号 : GC48956An internal standard for the quantification of penicillamine
Cas No.:2925655-01-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Penicillamine-d3 is intended for use as an internal standard for the quantification of penicillamine by GC- or LC-MS. Penicillamine is an orally bioavailable copper chelator and penicillin degradation product.1,2 It increases urinary and fecal copper excretion and decreases liver copper concentration in a rat model of copper overload when administered at 0.67 mmol/kg per day, but does not affect kidney, spleen, or brain copper levels.3 Penicillamine (100 mg/kg per day) dissolves copper-rich granules in hepatic lysosomes of Long-Evans cinnamon (LEC) rats, which spontaneously develop hepatic injury and acute hepatitis and have a mutation homologous to that of the human Wilson disease gene.4 Penicillamine has anticonvulsant and proconvulsant effects in mice when administered at 0.5 and 250 mg/kg, respectively, which are blocked by the nitric oxide synthase (NOS) inhibitors L-NAME and 7-nitroindazole .5 Formulations containing penicillamine have been used to treat Wilson disease, cystinuria, and active rheumatoid arthritis.
1.Delangle, P., and Mintz, E.Chelation therapy in Wilson's disease: From D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelatorsDalton Trans.41(21)6359-6370(2012) 2.Abraham, E.P., Chain, E., Baker, W., et al.Penicillamine, a characteristic degradation product of penicillinNature151(3821)107(1943) 3.Domingo, J.L., GÓmez, M., and Jones, M.M.Comparative efficacy of several potential treatments for copper mobilization in copper-overloaded ratsBiol. Trace Elem. Res.74(2)127-139(2000) 4.Klein, D., Lichtmannegger, J., Heinzmann, U., et al.Dissolution of copper-rich granules in hepatic lysosomes by D-penicillamine prevents the development of fulminant hepatitis in Long-Evans cinnamon ratsJ. Hepatol.32(2)193-201(2000) 5.Rahimi, N., Sadeghzadeh, M., Javad-Paydar, M., et al.Effects of D-penicillamine on pentylenetetrazole-induced seizures in mice: involvement of nitric oxide/NMDA pathwaysEpilepsy Behav.3942-47(2014)
Cas No. | 2925655-01-0 | SDF | |
别名 | D-(-)-Penicillamine-d3 | ||
Canonical SMILES | CC(C([2H])([2H])[2H])(S)[C@@H](N)C(O)=O | ||
分子式 | C5H8D3NO2S | 分子量 | 152.2 |
溶解度 | Water: soluble | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 6.5703 mL | 32.8515 mL | 65.703 mL |
5 mM | 1.3141 mL | 6.5703 mL | 13.1406 mL |
10 mM | 0.657 mL | 3.2852 mL | 6.5703 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。